Translational Research Program | Funding | Pappendick Family Therapeutic Acceleration Award

Full Application due: March 9, 2020
Funding Commences: July 1, 2020

All materials should be submitted to the TRP.

Download the application instructions.

Contact the TRP at trp@childrens.harvard.edu with any questions.

Background

The goal of the Pappendick Family Therapeutic Acceleration Award is to facilitate investigators getting their late preclinical and early clinical phase 1 studies accomplished in order to allow investigators to more rapidly pursue their research which could ultimately impact the lives of pediatric patients suffering from serious or life-threatening diseases. The Translational Research Program (TRP) has created this new initiative to provide support to investigators in two spheres:

  • Late pre-clinical studies
  • Early clinical phase 1 studies

Purpose of grant

The program seeks to accelerate studies with clear paths to market/IP.

Funding details

Funding through the Pappendick Family Award is available in the form of two-year awards with up to $100k/year (inclusive of 20% overhead) available. The TRP anticipates awarding two awards per year.

Eligibility

Applications will be accepted from Principal Investigators (PIs) who are full-time faculty of Boston Children’s Hospital. For phase 1 studies, at time of application, if not already open and accruing patients, the trial should be ready to open within the upcoming 6-months. Those studies representing translation of scientific discoveries from BCH, particularly first in human studies, or trials in which BCH is the lead site will have priority. Any IP generated is expected to remain at BCH.

Process

Applications will be accepted on yearly basis and will be reviewed by an external review committee consisting of translational research and clinical trial experts from outside Boston Children’s Hospital as well as members of the Venture Philanthropy Network.

Review criteria: Applications will be prioritized for funding based on the review panel’s evaluation of the following:

  1. The likely impact of research on child health with a clear path to market.
  2. The role of BCH basic/discovery and translational research in development of the research and, compelling nature of the need.
  3. The track record of the investigative team in carrying out late preclinical and/or human early phase therapeutic and device trials.

These aspects should be covered in the application.

Signatures

The signature of the primary investigator (and co-investigator) is required. Additionally, the signature of the primary investigator’s Department Chairman or Division Chief’s signature is required.

Full applications

Research plan/proposal (not to exceed 5 pages, including figures but excluding references) should include a summary of the study and its goal as well as a strong justification for why funding is needed and an explanation of how this funding will accelerate the research and path to market. Proposal text must be limited to five pages (including figures but excluding references).

Additional items to be included as an appendix (not included in 5-page limit) are requested:

  • IRB approval letter (if applicable)
  • FDA (IND/IDE) approval (if applicable)
  • Summary notes from IND/IDE Review Group (IIRG) meeting (if appropriate)
  • Current (if any) funding for study
  • Reviewer comments from grants that fund any part of the trial

Required format

Full applications must be submitted in single spaced text, one-half inch margins, and no smaller than an 11-point font. Arial or Helvetica typeface is preferred. The primary applicant’s name must appear in the upper right-hand corner of each page. Standard NIH forms for abstracts, NIH biosketch, and other support may be used and may be submitted as separate files. Applications must be submitted electronically, including the letter of support from Department Chair/Division Chief.

Send a PDF file of assembled proposal to TRP@childrens.harvard.edu.

Letter of Support

Full applications must include a letter of support from the primary applicant’s chairperson. Included in the letter of support must be a statement regarding the importance of the research to the field and priority of the trial for the department/division, including prioritization of the patient population to be enrolled in the trial. The Chairperson should affirm that the applicant will have the support of the Department/Division to carry out the proposed studies.

Composition of Research Proposal

Invited research proposals should include:

  1. Face Page
  2. Abstracts (scientific and lay)
  3. Table of Contents
  4. Detailed Budget
  5. Budget justification
  6. Biosketch(es) (include PI and co-investigator; NIH format)
  7. Other support
  8. Research Plan (5-page limit), including the following items: The role of BCH basic/discovery and translational research in development of the clinical trial, compelling nature of the need and the track record of the investigative team in carrying out human early phase therapeutic and device trials.
  9. Literature cited
  10. Appendix
    • IRB approval (if applicable)
    • FDA approval (if applicable)
    • Summary notes from IIRG meeting (if appropriate)
    • Current funding outline for study
    • Reviewer comments from grants that fund any part of the trial
    • Letters of support from Department/Division chairperson.
    • Letters of support collaborators or consultants are optional.